

Office Action of April 28, 2008 for record purposes.

DETAILED ACTION

1. The Amendment filed January 11, 2008 in response to the Office Action of October 11, 2007 is acknowledged and has been entered. Previously pending claims 6, 7 and 17 have been cancelled, claims 4, 5, and 8-10 have been amended
2. Claims 4, 5, and 8-10 are currently being examined.
3. The following rejections are being maintained:

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 4, 8, and 9 remain rejected under 35 USC 112, first paragraph for the reasons previously set forth in the Office Action of October 11, 2007, section 12-pages 13-19.

Applicants argue that with respect to the Examiner's assertion that the nucleic acid set forth in SEQ ID NO: 3 can code for a protein or polypeptide that is present in the nucleus of the animal cell, the nucleic acid set forth in SEQ ID NO: 3 can be present both in the nucleus and the cytoplasm.

Applicants argue that in order to assist the Examiner, claim 4, upon which claim 8 also depends, has been amended to define the nucleic acid recited in the claims as the nucleic acid set forth in SEQ ID NO: 3 and a nucleic acid strand that is completely complementary to the nucleic acid set forth in SEQ ID NO: 3. As acknowledged by the Examiner in the Office Action, the present application discloses SEQ ID NO: 3. The present application discloses that the term "nucleic acid of the present invention" can include a complementary strand selected from information of the nucleic acid set forth in SEQ ID NO: 3 (page 22). As is also acknowledged by

the Examiner, it is known in the art that the phrase "complementary strands of nucleic acids" can include nucleic acids that are completely complementary to the claimed polynucleotide.

Applicants arguments have been considered, but have not been found persuasive as the claims are still drawn to fragments of SEQ ID NO: 3. Claims 4, 7, and 9 are drawn to "A recombinant vector comprising **a purified nucleic acid coding for a** (emphasis added) protein or polypeptide . . . wherein the nucleic acid is set forth **in** (emphasis added) SEQ ID NO: 3 or is a nucleic acid that is completely complementary to the nucleic set forth **in** (emphasis added) SSEQ ID NO: 3. . . ." and a host cell transformed with the vector and a method of producing the protein. This claim construction clearly reads on fragments of SEQ ID NO: 3 as the claims are not drawn to the protein or polypeptide produced from a nucleic acid comprising SEQ ID NO: 3. The claims are not enabled to make a fragment of SEQ ID NO: 3 that is present in the nucleus and which has a transcription factor function and/or a function that can induce expression of retinoblastoma gene or a gene product thereof, given that the specification has not identified the regions of the encoded polypeptide that are required for these functions and given the unpredictability of protein biochemistry and predicting function from structure previously set forth. Thus undue experimentation would be required to identify fragments that encode a protein with the claimed functions.

Applicant's arguments have not been found persuasive and the rejection is maintained.

5. Claims 4, 8 and 9 remain rejected under 35 USC 112, first paragraph for the reasons previously set forth in the Office Action of October 11, 2007, section, 13, pages 19-24.

Applicants argue that in order to assist the Examiner, claim 4, upon which claim 8 also depends, has been amended to define the nucleic acid recited in the claims as the nucleic acid set

forth in SEQ ID NO: 3 and a nucleic acid strand that is completely complementary to the nucleic acid set forth in SEQ ID NO: 3. As acknowledged by the Examiner in the Office Action, the present application discloses SEQ ID NO: 3. As is also acknowledged by the Examiner, it is known in the art that the phrase "complementary strands of nucleic acids" can include nucleic acids that are completely complementary to the claimed polynucleotide.

Applicants arguments have been considered, but have not been found persuasive as the claims are still drawn to fragments of SEQ ID NO: 3. Claims 4, 8, and 9 are drawn to "A recombinant vector comprising a **purified nucleic acid coding for a** (emphasis added) protein or polypeptide . . . wherein the nucleic acid is set forth **in** (emphasis added) SEQ ID NO: 3 or is a nucleic acid that is completely complementary to the nucleic set forth **in** (emphasis added) SSEQ ID NO: 3. . . ." and a host cell transformed with the vector and a method of producing the protein. This claim construction clearly reads on fragments of SEQ ID NO: 3 as the claims are not drawn to the protein or polypeptide produced from a nucleic acid comprising SEQ ID NO: 3. Thus, the claims are not enabled to make a fragment of SEQ ID NO: 3 that is present in the nucleus and which has a transcription factor function and/or a function that can induce expression of retinoblastoma gene or a gene product thereof given that the specification has not identify the regions of the encoded polypeptide that are required for these functions and undue experimentation would be required to identify fragments that encode a protein with the claimed functions. The level of skill and knowledge in the art is such that one of ordinary skill would not be able to identify without further testing which of these fragment of SEQ ID NO: 3 can code for a protein have the ability to be present in the nucleus and which has a transcription factor function and/or a function that can induce expression of retinoblastoma gene or a gene product

thereof. Thus one of skill in the art would not recognize that Applicants were in possession of the claimed genus.

Applicant's arguments have not been found persuasive and the rejection is maintained.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

6. Claims 8-10 remain rejected and claims 4 and 5 are rejected under 35 U.S.C. 102(a) as being anticipated by Chano et al. (Oncogene, February 14, 2002, 21:1295-1298, IDS) for the reasons forth in the Office Action of October 11, 2007, section, 15, pages 25-27.

Applicants argue that three of the authors listed in Chano et al., Chano, Ikegawa, and Okabe, are the also the inventors of the present application. The remaining three authors listed in Chano et al., Kontani, Baldini, and Saeki, were working under the direction of the present inventors and their contributions were not of an inventive nature. Applicants submit herewith a Declaration under 37 C.F.R. § 1.132 to further establish that the authors of Chano et al. are the inventors of the present application. As such, Applicants respectfully submit that Chano et al. does not qualify as an invention known or used by "others" within the meaning of 35 U.S.C. §102(a).

The Declaration under 37 CFR 1.132 filed January 11, 2008 is insufficient to overcome the rejection of claims 4, 5 and 8-10 based upon Chano et al. (Oncogene, February 14, 2002, 21:1295-1298, IDS) as set forth in the last Office action because: The Declarants state in section 1:

We, Tokuhiko Chano, Shiro Ikegawa, and Hidetoshi Okabe, do declare and state as follows: **We are three of the six named inventors** (emphasis added) of the present application identified above.

Given the statement that “We are three of the six named inventors” and the identity of the other three inventors has not been made known to the Office nor have six inventors signed the Declaration, the Declaration under 37 CFR 1.132 is not an unequivocal statement from the Applicant regarding the subject matter disclosed in the article and has not properly executed, see MPEP 716.10 and CFR 1.63. Thus, the Declaration under 37 CFR 1.132 filed January 11, 2008 is insufficient to overcome the rejection.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

7. Claim 10 remains rejected under 35 U.S.C. 103(a) as being unpatentable over AB059622 (October 11, 2001), in view of Mensink et al (British J. Haematol. (August 1998) 102:768-774) and further in view of Buck et al (Biotechniques (1999) 27(3):528-536) for the reasons forth in the Office Action of October 11, 2007, section, 16, pages 28-30.

Applicants argue that as acknowledged by the Examiner, AB059622 does not teach the particular primers of SEQ ID Nos: 19 and 20. Mensink et al. and Buck et al. also do not, alone or in combination, teach or suggest SEQ ID Nos: 19 and 20. With reference to the Examiner's

assertion that published sequences may be analyzed by commercially available software for primer selection in many cases, one can use the "Primer 3 website" (primer3.sourceforge.net) for this purpose rather than the commercially available software taught in Mensink et al. Simply by knowing the nucleotide sequence information, one can use the "Primer 3 website" to analyze primer design with general versatility. However, only after using the designed primer, can one obtain useful information on whether or not it is applicable to an experiment or clinical. Thus, one cannot determine if a nucleotide sequence is useful, simply because the sequence is known. Accordingly, one of ordinary skill in the art would not be able to arrive at the particular primers of SEQ ID NOs: 19 and 20, simply because of the disclosure of AB059622.

Applicants arguments have been considered, but have not been found persuasive because of the availability in the art of primer design programs in the art at the time the invention was made and the teaching of Buck that every single primer tested of the 164 primers tested functioned as expected, one of skill in the art would have a reasonable expectation of success given that sequence was known in the art at the time the invention was made.

Applicant's arguments have not been found persuasive and the rejection is maintained.

New Grounds of Rejection
Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

8. Claims 4, 5, and 8 are rejected under 35 U.S.C. 102(b) as being anticipated by Nagase et al. (DNA Research, 1996, 3:321-329) as evidenced by Nomura et al. (DNA Research,

1994: 1: 27-35), Chano et al. (Oncogene, February 14, 2002, 21:1295-1298, IDS) and Appendix 1.

The claims are drawn to:

4. A recombinant vector comprising a purified nucleic acid coding for a protein or polypeptide which is present in nucleus of human or animal cell and which has a transcription factor function and/or a function that can induce expression of retinoblastoma gene (RB 1 gene) or a gene product thereof the polypeptide or protein according to claim 1, or a complementary strand thereof, wherein the nucleic acid is set forth in SEQ ID No: 3 or is a nucleic acid strand that is completely complementary to the nucleic acid set forth in SEQ ID No: 3.

5. A recombinant vector comprising a nucleic acid hybridizing under stringent conditions with the a purified nucleic acid set forth in SEQ ID No: 3 or a nucleic acid strand that is completely complementary to the nucleic acid set forth in SEQ ID No: 3 according to claim 3 or the complementary strand thereof; wherein the stringent conditions comprise a condition under which a positive hybridization signal is still observed even after heating at 42 °C in a solution of 6 x SSC, 0.5% SDS and 50% formamide, and washing at 68 °C in a solution of 0.1 x SSC and 0.5% SDS.

8. A transformant that was transformed with the recombinant vector according to claim 4.

Nagase et al. teach the cloning of the cDNA KIAA0203, which 99.3% identical to SEQ ID NO: 3 and codes for a protein identical to RB1CC1, see Table 1 of Nagase et al. and Appendix 1. Nagase et al. used the methods Nomura et al. for cloning the cDNA, see Materials and Methods. and reference 1 of Nagase et al. Nomura et al. teach that cDNA were cloned and

placed into the pBluescript SK+ cDNA vector and used to make cDNA libraries that were grown in colonies of cells, see p. 28, 1st col., of Nomura et al.

Chano et al. teach that RB1CC1 can induce the expression of the RB1 gene, see Abstract, Fig. 2 and Fig.4.

Although the reference does not specifically state that KIAA0203 codes for a protein or polypeptide which is present in nucleus of human or animal cell and which has a transcription factor function and /or a function that can induce expression of retinoblastoma gene (RB1 gene) or a gene product thereof, given the teaching of Chano et al. The claimed product appears to be the same as the prior art product, absent a showing of unobvious differences. The office does not have the facilities and resources to provide the factual evidence needed in order to establish that the product of the prior art does not possess the same material, structural and functional characteristics of the claimed product. In the absence of evidence to the contrary, the burden is on the applicant to prove that the claimed product is different from those taught by the prior art and to establish patentable differences. See *In re Best* 562F.2d 1252, 195 USPQ 430 (CCPA).

Claim Rejections - 35 USC § 103

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

9. Claims 4, 5, 8, and 9 are rejected under 35 U.S.C. 103(a) as being unpatentable over AB059622 (October 11, 2001) as evidenced by Chano et al. (Oncogene, February 14, 2002, 21:1295-1298, IDS), in view of US Patent No. 4,889,806 (Dec. 1989) and Sambrook et al (Molecular Cloning, A Laboratory Manual, Cold Spring Harbor, 1989, pp.16.3-4).

The claims are drawn to:

4. A recombinant vector comprising a purified nucleic acid coding for a protein or polypeptide which is present in nucleus of human or animal cell and which has a transcription factor function and/or a function that can induce expression of retinoblastoma gene (RB 1 gene) or a gene product thereof the polypeptide or protein according to claim 1, or a complementary strand thereof, wherein the nucleic acid is set forth in SEQ ID No: 3 or is a nucleic acid strand that is completely complementary to the nucleic acid set forth in SEQ ID No: 3.

5. A recombinant vector comprising a nucleic acid hybridizing under stringent conditions with the a purified nucleic acid set forth in SEQ ID No: 3 or a nucleic acid strand that is completely complementary to the nucleic acid set forth in SEQ ID No: 3 according to claim 3 or the complementary strand thereof; wherein the stringent conditions comprise a condition

under which a positive hybridization signal is still observed even after heating at 42 °C in a solution of 6 x SSC, 0.5% SDS and 50% formamide, and washing at 68 °C in a solution of 0.1 x SSC and 0.5% SDS.

8. A transformant that was transformed with the recombinant vector according to claim 4.

9. A method for producing a protein or polypeptide which is present in the nucleus of a human or animal cell and which has a transcription factor function and/or a function that can induce expression of retinoblastoma gene (RB 1 gene) or a gene product thereof or a complementary strand thereof, wherein the nucleic acid is set forth in SEQ ID NO" 3 the polypeptide or protein according to claim 1 , comprising a step of culturing the transformant according to claim 8 with the recombinant vector containing nucleic acid coding for the polypeptide or protein.

AB059622 teaches as previously set forth in the Office Action of October 11, 2007, section 14, pages 24-25, but does not teach a recombinant vector comprising SEQ ID NO: 3, a transformant transformed with the recombinant vector, or a method for producing protein using the recombinant vector.

US Patent No. 4,889,806 teach that with the advent of recombinant DNA and molecular cloning technology it is now conventional to transfer genetic information into plasmids or vectors constructed in vitro and then transferred into host cells and clonally propagated (col. 1, lines 18-24).

Sambrook et al teach that cloned genes are conventionally expressed using expression vectors and that expression of cloned proteins have been used to: (1) confirm the identity of a cloned gene by using immunological or functional assays to detect the encoded protein; (2)

produce large amounts of proteins of biological interest that are normally available in only limited quantities from natural sources; (3) to study the biosynthesis and intracellular transport of proteins following their expression in various cell types; and (4) to elucidate structure-function relationships by analyzing the properties of normal and mutant proteins (para bridging pages 16.3 and 16.4).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to make a recombinant vector with the nucleic acid sequence of AB059622, transform the vector into a host cell and produce a protein with the methods of Sambrook et al and US Patent No. 4,889,806 because US Patent No. 4,889,806 specifically teaches that it is conventional to transfer genetic materials into plasmids or vectors and then transfer the plasmids or vectors into host cells and clonally propagate the genetic material and because Sambrook et al teach that cloned genes are conventionally expressed using expression vectors.

One of ordinary skill in the art at the time the invention was made would have been motivated to make a recombinant vector with the nucleic acid sequence of AB059622 with the methods of Sambrook et al and US Patent No. 4,889,806 because Sambrook et al specifically teach that expressed cloned proteins are used to: (1) confirm the identity of a cloned gene by using immunological or functional assays to detect the encoded protein; (2) produce large amounts of proteins of biological interest that are normally available in only limited quantities from natural sources; (3) to study the biosynthesis and intracellular transport of proteins following their expression in various cell types; and (4) to elucidate structure-function relationships by analyzing the properties of normal and mutant proteins. Given the conventional nature of the methods, one of skill in the art would have had a reasonable expectation of success.

Priority

10. Applicants state that at page 2, item 6, of the Office Action, the Examiner has acknowledged receipt of papers submitted under 35 U.S.C. § 119(a)-(d), which papers have been placed of record in the file. The Examiner recognizes a priority date of January 30, 2003. The Examiner indicates that because the priority of the instantly claimed invention is based on Japanese Application Nos. 2002-161400 and 2002-214978, and translations have not been provided, the Examiner is unable to recognize an earlier priority date. The Examiner suggests that Applicants submit a translation of the priority documents and to point to page and line where support can be found establishing an earlier priority date.

Applicants argue that English translations are not required for claiming priority. According to MPEP § 201.15, the actual merits of an applicant's claim of priority is considered by the Examiner only when a reference is found with an effective date between the date of the foreign filing and the date of filing in the United States. None of the publication dates of the references cited by the Examiner appears to fall within this range. As such, the priority dates of the Japanese applications should be recognized.

Applicants' arguments have been considered and the conditions for foreign priority Japanese Application Nos. 2002-161400 and 2002-214978 have been met.

11. All other objections and rejections recited in Office Action of October 11, 2007 are withdrawn.

12. No claims allowed.

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Peter J. Reddig whose telephone number is (571) 272-9031.

The examiner can normally be reached on M-F 8:30 a.m.-5:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on (571) 272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Peter J Reddig/

Examiner, Art Unit 1642

/P. J. R./

/Karen A Canella/

Primary Examiner, Art Unit 1643

Appendix 1

D86958						
LOCUS	D86958	6614 bp	mRNA	linear	FRI 15-JAN-2004	
DEFINITION	Homo sapiens mRNA for KIAA0203 gene, partial cds.					
ACCESSION	D86958					
VERSION	D86958.1 GI:1503989					
KEYWORDS	.					
SOURCE	Homo sapiens (human)					
ORGANISM	Homo sapiens					
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;					
	Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;					

Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Nagase,T., Seki,N., Ishikawa,K., Ohira,M., Kawarabayashi,Y.,
 Ohara,O., Tanaka,A., Kitanishi,H., Miyajima,N., and Nomura,N.
 TITLE Prediction of the coding sequences of unidentified human genes. VI.
 The coding sequences of 80 new genes (K1AA0201-K1AA0280) deduced by
 analysis of cDNA clones from cell line KG-1 and brain
 JOURNAL DNA Res. 3 (5), 321-329 (1996)
 PUBLISHED 9039502

REFERENCE 2 (bases 1 to 6614)
 AUTHORS Ohara,O., Nagase,T., Kikuno,R. and Nomura,N.
 TITLE Direct Submission
 JOURNAL Submitted (02-AUG-1996) Osamu Ohara, Kazusa DNA Research Institute;
 1532-3, Yana, Kisarazu, Chiba 292-0812, Japan
 (E-mail:odnainfo@kazusa.or.jp, Tel:+81-438-52-3913)

FEATURES
 source
 1. .6614
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /chromosome="9g"
 /sex="male"
 /cell_line="KG-1"
 /cell_type="myeloblast"
 gene
 <1. .6614
 /gene="K1AA0203"
 5'UTR
 1. .515
 /gene="K1AA0203"
 CDS
 <510. .5291
 /gene="K1AA0203"
 /note="Start codon is not identified
 similar to mouse CCl.""
 /citation=[1]
 /codon_start=1
 /protein_id="EAA13194.2"
 /db_xref="GI:40788906"
 /translation="MIIMKLIVPLVNTGTTITFDTELTQTVADLKHAIQSKYKIAIQH
 QVIVNVNGGECMAADRRVCTYSAGTDNPIFENKEMILDRPAPAKTTSTENDMEI
 KVBSIIMPAVHTVASRTQALAMEYVAKKLQSPCEGLVHDEHLQHQQWAAIMANLE
 DCSNSYQKLLPKFSEIYSNYLQSIEDIKILKTLHGTAVSVMAKIPLECLTHSYREK
 LGRLOSLPEHDESEKATKRTSTELVLSFDMPTATNSELTSFPKSVHVSPTDADAES
 GKRETSQCQSTVHQDDETTITDKDGLPFFNVSLLDWINVQDRPNDSVLRKCFDSM
 SRLDPRIIRPFTAEQRQTIKLNQNMKAIKGLDRLYALDQMIASGRLVNEQKELA
 QGFLANQKRAENLKDASVLDPLCLSHANQIMLMQNHKLLDQKQCTAKQELANL
 HVRLKWCQFVMLHADQDGEKLQALRLVIELLERVKIVEALSTVPMQYCLAVVEVRR
 KMFILHYREWAGALVKDGRKLYAEKSKRESFGKLFKSLNNALFRGLDSWPPSFCT
 QKPRKFDCELPDISLKDQLQFLQSPCEQVQFLRVPLLCDEPLHGHVIALHNLVKA
 QSLDEMSQTTIDLLSEQKASVSQTS PQSASSPRMESTAGITTTTSPRTPPPLTVQDPL
 CPAVCFLEELSPDSIDAHFTDFDTTIPHNIQTIQHVSLODLSLAESESPDFMSAVNE
 FVIEENLSSPNFISDPQSPMMVESLYSSVINADSRMRQDNTNVCGRDFGDHSTLNV
 QLEKRCRVAGDSHFSIQTKEDLCHFRITFVQKQDQDFNSLKCTAVEIRNIIKVKGS
 LEITLKEKHQKELLGLKMEYVEKLDLKEITENEMKIKKLKSELVCLVLEVLQNKNE
 FALVKHEKAVILCLQNEKQDKLLEMNIMHSQNCIEKLQGREIVLEDLKLLHEND
 EKLQLLRAELQSLQSHLKEEDTLQVRHIEQFEKVMTHDRVSVLEELKKENQIINQI
 QESHAETIQEKELQELKLVSDLSOTRCKLEVEALKEATDEIKILLEESRAQOK
 ETLKLSLEQETENLRTIEKILNKQIOMNNENYQVGLAEELRTMTIEKQDCISELISRH
 EESNILEKAEINKVTSLHNQAFIEKLNKEQIIELOSKLOSELALERQKDEKIQOE
 EKYEAITQNLKEDRQKLVSSQEDRQELQIKLNCERKDEAIQTALKEFKLREVEVEKL
 LEKVKHLENQIAKSPAIIDSTRGSSSVLAELOKLEQKLEAKFQLQEEQEKKNEMQ
 NVRTSLIAEQQTNNFTVLTREKMKENIINDLSOKLKTQKQERDOKLIESLSESDRA
 RLLLEKKKLEEVSKLRSFVPSYPVATAPLYGACAPELPQSDRSASVETADEGRV
 DSAMEITSMSSVQENIHMLSEKQRIIMLELRTQLKHEENKRLNQLMSQMSVSSRH
 SEKIAITRDPQGVQDLVLIIDLRHONYVLPFVSPILYFLHSSELPAIDLKPAASGASRP
 WVLGKVMKEIKYQAKKAQNRKPVLTGTFFYRVKAVSNNKKV"
 5292. .6614
 /gene="K1AA0203"

3'UTR
 5292. .6614

ORIGIN

Query Match		99.3%	Score 6587;	DB 5;	Length 6614;	
Best Local Similarity		99.8%	Pred. No. 0;			
Matches 6609;		Conservative	0;	Mismatches	5;	Indels 9; Gaps 1;
Qy	10	AACAAACCAAGCCGCGCGCGTGTCCGCGGCCCTGCCGAGCCCTCGGGGTTCGCTCAGAAAT				69
Db	1	AACAAACCAAGCCGCGCGCGTGTCCGCGGCCCTGCCGAGCCCTCGGGGTTCGCTCAGAAAT				60
Qy	70	CCCCAGTCGCTGCGCCCTCGGCTCTGACAGCGCGCGGCTTCTGTCCCGCGGCCCA				129
Db	61	CCCCAGTCGCTGCGCCCTCGGCTCTGACAGCGCGCGGCTTCTGTCCCGCGGCCCA				120
Qy	130	GACCCAGAGCCGAGGGGCTGCTCGGCTCCTTGTCCGCGCGGACCCCTCCCTGCCTCCTA				189
Db	121	GACCCAGAGCCGAGGGGCTGCTCGGCTCCTTGTCCGCGCGGACCCCTCCCTGCCTCCTA				180
Qy	190	GAGTTCGGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGTGTGTGCGCTTAGCGGT				249
Db	181	GAGTTCGGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGTGTGTGCGCTTAGCGGT				240
Qy	250	GCCGAATGGGCGGTTGTTAACCGCTGCCGAGGACTAGGCGGCGCGCGGAAGATGGTGC				309
Db	241	GCCGAATGGGCGGTTGTTAACCGCTGCCGAGGACTAGGCGGCGCGCGGAAGATGGTGC				300
Qy	310	GGTGTGCTGCTCTGCTGCTGCCGCGCGCGAAGGAGGCGGTTCGCGGTTTTCTGAGTT				369
Db	301	GGTGTGCTGCTCTGCTGCTGCCGCGCGCGAAGGAGGCGGTTCGCGGTTTTCTGAGTT				360
Qy	370	TAACCCAGTAATGCCATTAGTTGCCAATCTCAAGCAAAACATAAGCCAGTTTTAAT				429
Db	361	TAACCCAGTAATGCCATTAGTTGCCAATCTCAAGCAAAACATAAGCCAGTTTTAAT				420
Qy	430	CTACTTTTTAAGAAAAGTGGTAGTCCTTTTCACAGTGCCGTGACGTAACTGTATCAGAGG				489
Db	421	CTACTTTTTAAGAAAAGTGGTAGTCCTTTTCACAGTGCCGTGACGTAACTGTATCAGAGG				480
Qy	490	TGAGGTATAAGCTCACAGAAATTCAGATAAAATCATGAAGTTATATGTATTTCTGGTTA				549
Db	481	TGAGGTATAAGCTCACAGAAATTCAGATAAAATCATGAAGTTATATGTATTTCTGGTTA				540
Qy	550	ACACTGGAACTACTCTAACATTGGACACTGAACCTTACAGTGCMAACTGTGGCAGACCTTA				609
Db	541	ACACTGGAACTACTCTAACATTGGACACTGAACCTTACAGTGCMAACTGTGGCAGACCTTA				600
Qy	610	AGCATGCCATTCAAAAGCAATACAAAGATTGCTATTCAACACCAAGGTGCTGGTGGTCAATG				669
Db	601	AGCATGCCATTCAAAAGCAATACAAAGATTGCTATTCAACACCAAGGTGCTGGTGGTCAATG				660
Qy	670	GAGGAGAAATGCATGGCTGCAGATCGAAGAGTGTGTACCTACAGTGCCTGGGACGGATACAA				729
Db	661	GAGGAGAAATGCATGGCTGCAGATCGAAGAGTGTGTACCTACAGTGCCTGGGACGGATACAA				720
Qy	730	ATCCAAATTTTTCTTTTTTAAACAAAGAAATGATCTTATGCGATCGTCAACCTGCTATTCTTA				789
Db	721	ATCCAAATTTTTCTTTTTTAAACAAAGAAATGATCTTATGCGATCGTCAACCTGCTATTCTTA				780
Qy	790	AAACTACCTTTTTCGACAGAAAAATGACATGGAAATAAAAGTTGAAGAAATCTCTTATGATGC				849
Db	781	AAACTACCTTTTTCGACAGAAAAATGACATGGAAATAAAAGTTGAAGAAATCTCTTATGATGC				840
Qy	850	CTGCAGTTTTTCATACATGTTGCTTCAAGSACACAGCTTGCAATTGGAATATGATGAAGTTG				909
Db	841	CTGCAGTTTTTCATACATGTTGCTTCAAGSACACAGCTTGCAATTGGAATATGATGAAGTTG				900
Qy	910	CCAAGAACTTTGTTCTTTTTTGTGAAGGCTTTGTACATGATGAACATCTTCAACACCAAG				969

Db 901 CCAAGAACTTTGTTCTTTTGTGAAGGTCCTGTACATGATGAACATCTTCAACACCAAG 960

Qy 970 GCTGGGCTGCAATCATGGCCAACTGGAGACTGTTCAAATTCATACCAAAAGCTACTTT 1029

Db 961 GCTGGGCTGCAATCATGGCCAACTGGAGACTGTTCAAATTCATACCAAAAGCTACTTT 1020

Qy 1030 TCAAGTTTGAAGTATTTATTCAAAATTATCTGCAGTCCATAGAGACATCAAGTTAAAAAC 1089

Db 1021 TCAAGTTTGAAGTATTTATTCAAAATTATCTGCAGTCCATAGAGACATCAAGTTAAAAAC 1080

Qy 1090 TTACTCATTTAGGAACTGCAGTTTCAGTAAATGGCCAAAGATTCACACTGTTGGAGTGCCTAA 1149

Db 1081 TTACTCATTTAGGAACTGCAGTTTCAGTAAATGGCCAAAGATTCACACTGTTGGAGTGCCTAA 1140

Qy 1150 CCAGACATAGTTACAGAGAATGTTTGGGAAGACTGGATTCTTTACCTGAACATGAAGACT 1209

Db 1141 CCAGACATAGTTACAGAGAATGTTTGGGAAGACTGGATTCTTTACCTGAACATGAAGACT 1200

Qy 1210 CAGAAAAAGCTGAGACGAAAAGATCCACTGAACCTGGTGCTCTCTCCTGATATGCCTAGAA 1269

Db 1201 CAGAAAAAGCTGAGACGAAAAGATCCACTGAACCTGGTGCTCTCTCCTGATATGCCTAGAA 1260

Qy 1270 CAACTAACGAATCTTTGTTAAACCTCATTTCCCAAGTCAGTGGACATGTGTGCCGAGATA 1329

Db 1261 CAACTAACGAATCTTTGTTAAACCTCATTTCCCAAGTCAGTGGACATGTGTGCCGAGATA 1320

Qy 1330 CCGCAGATGCTGAAAGTGGCAAAAGAAATAGGGAACTTTGTCAAAGTACTGTTCAATCAGC 1389

Db 1321 CCGCAGATGCTGAAAGTGGCAAAAGAAATAGGGAACTTTGTCAAAGTACTGTTCAATCAGC 1380

Qy 1390 AAGATGAAACTACGATTGACACTAAAGATGGTGATCTGCGCCTTTTTTAATGTCCTTTGT 1449

Db 1381 AAGATGAAACTACGATTGACACTAAAGATGGTGATCTGCGCCTTTTTTAATGTCCTTTGT 1440

Qy 1450 TAGACTGGATAAAATGTTCAAGATAGACCTAATGATGTGGAATCTTTGGTCAGGAAGTGCT 1509

Db 1441 TAGACTGGATAAAATGTTCAAGATAGACCTAATGATGTGGAATCTTTGGTCAGGAAGTGCT 1500

Qy 1510 TTGATTCTATGAGCAGGCTTGATCCAAAGGATTATTGACACATTATAGCAGAATGCCGTC 1569

Db 1501 TTGATTCTATGAGCAGGCTTGATCCAAAGGATTATTGACACATTATAGCAGAATGCCGTC 1560

Qy 1570 AAACATTGCCAAACTTGATTAATCAGAAATGAAAGCCATTAAAGGACTTGAAGATCGGC 1629

Db 1561 AAACATTGCCAAACTTGATTAATCAGAAATGAAAGCCATTAAAGGACTTGAAGATCGGC 1620

Qy 1630 TCTACGCCCTGGACACAGATGATTGCTAGCTGTGGCCGACTGGTGAATGAACAGAAAGAGC 1689

Db 1621 TCTACGCCCTGGACACAGATGATTGCTAGCTGTGGCCGACTGGTGAATGAACAGAAAGAGC 1680

Qy 1690 TTGCTCAGGGATTTTTAGCTAATCAGAAGAGAGCTGAAAACCTTAAAGGATGCATCTGTAT 1749

Db 1681 TTGCTCAGGGATTTTTAGCTAATCAGAAGAGAGCTGAAAACCTTAAAGGATGCATCTGTAT 1740

Qy 1750 TACCTGATTTATGCTGAGTCACGCAAAATCAGTTGATGATTATTGTGCAAAATCATAGAA 1809

Db 1741 TACCTGATTTATGCTGAGTCACGCAAAATCAGTTGATGATTATTGTGCAAAATCATAGAA 1800

Qy 1810 AACTGTTAGATATTAAAGCAGAAGTGTACCACTGCCAACAAGAACTAGCAAAATAACCTAC 1869

Db 1801 AACTGTTAGATATTAAAGCAGAAGTGTACCACTGCCAACAAGAACTAGCAAAATAACCTAC 1860

Qy 1870 ATGTCAGACTGAAGTGGTGTGCTTTGCTTAATGCTTCATGCTGATCAAGATGGAGAGAAGT 1929

Db 1861 ATGTCAGACTGAAGTGGTGTGCTTTGCTTAATGCTTCATGCTGATCAAGATGGAGAGAAGT 1920

Qy 1930 TACAAGCTTTGCTCCGCTCGTAAATAGAGCTGTGTAGAAAGAGTCAAAATGTTGAAGCTC 1989

Db	1921		TACAGGCTTTGCTCCGCGCTCGTAATAGAGCTGTTAGAAAGAGTCAAAATGTTGTGAAGCTC	1980
Qy	1990	TTAGTACAGTTCCCTCAGATGTACTGCTTAGCTGTTGTCAGGTTGTAACAAAGAAAATGT	2049	
Db	1981	TTAGTACAGTTCCCTCAGATGTACTGCTTAGCTGTTGTCAGGTTGTAACAAAGAAAATGT	2040	
Qy	2050	TCATAAAACACTACAGGAGTGGGCTGGTGCTTAGTCMAAGATGGAAAGAGATTATATG	2109	
Db	2041	TCATAAAACACTACAGGAGTGGGCTGGTGCTTAGTCMAAGATGGAAAGAGATTATATG	2100	
Qy	2110	AAGCAGAAAAATCAAAAAGGGAATCCTTTGGGAAATTATTTAGGAAGTCTTTTTTAAGAA	2169	
Db	2101	AAGCAGAAAAATCAAAAAGGGAATCCTTTGGGAAATTATTTAGGAAGTCTTTTTTAAGAA	2160	
Qy	2170	ATCGTCTGTTTAGGGGACTGGACTCCTGGCCCCCTTCCTTTGTACTCAAAAGCCTCGAA	2229	
Db	2161	ATCGTCTGTTTAGGGGACTGGACTCCTGGCCCCCTTCCTTTGTACTCAAAAGCCTCGAA	2220	
Qy	2230	AGTTTGACTGTGAACCTCCAGATATTTCAATTAAGAGTTTACAGTTTCGCAATCATTTT	2289	
Db	2221	AGTTTGACTGTGAACCTCCAGATATTTCAATTAAGAGTTTACAGTTTCGCAATCATTTT	2280	
Qy	2290	GTCCCTCGGGAAGTTCAGCCATTCTCTCAGGGTTCCTTACTTTGTGACTTTGAACTCTAC	2349	
Db	2281	GTCCCTCGGGAAGTTCAGCCATTCTCTCAGGGTTCCTTACTTTGTGACTTTGAACTCTAC	2340	
Qy	2350	ACCAGCATGTACTTGCTCTACATAAATTGGTAAAAGCAGCAAAAGTTGGATGAAATGT	2409	
Db	2341	ACCAGCATGTACTTGCTCTACATAAATTGGTAAAAGCAGCAAAAGTTGGATGAAATGT	2400	
Qy	2410	CACAGACCATTACAGATCTACTGAGTGAACAAAAGGCATCTGTGAGCCAGACATCCCCAC	2469	
Db	2401	CACAGACCATTACAGATCTACTGAGTGAACAAAAGGCATCTGTGAGTCAAGACATCCCCAC	2460	
Qy	2470	AGTCTGCTTCTGCACCAAGATGGAAGTACAGCAGGAATTACAACACTACCTCACCGA	2529	
Db	2461	AGTCTGCTTCTGCACCAAGATGGAAGTACAGCAGGAATTACAACACTACCTCACCGA	2520	
Qy	2530	GAACTCCTCCACCACTGACTGTTTCAGGATCCCTTATGCTCGAGTTTGTCCCTTAGAAG	2589	
Db	2521	GAACTCCTCCACCACTGACTGTTTCAGGATCCCTTATGCTCGAGTTTGTCCCTTAGAAG	2580	
Qy	2590	AATTATCTCCAGATAGTATTGATGCACATACGTTTGATTTTGAACATTCCCATCCAA	2649	
Db	2581	AATTATCTCCAGATAGTATTGATGCACATACGTTTGATTTTGAACATTCCCATCCAA	2640	
Qy	2650	ACATAGAACAGACTATTACCAAGTTTCTTTAGACTTGGATTCAITAGCAGAAAGTCCGT	2709	
Db	2641	ACATAGAACAGACTATTACCAAGTTTCTTTAGACTTGGATTCAITAGCAGAAAGTCCGT	2700	
Qy	2710	AATCAGATTTTATGTCGTGTGAATGAGTTTGTAAATAGAAGAAAATTTGCGCTCCTTA	2769	
Db	2701	AATCAGATTTTATGTCGTGTGAATGAGTTTGTAAATAGAAGAAAATTTGCGCTCCTTA	2760	
Qy	2770	ATCCTATAAGTGATCCACAAAGCCAGAAATGATGGTGAATCAGTTTATTCATCAGTTA	2829	
Db	2761	ATCCTATAAGTGATCCACAAAGCCAGAAATGATGGTGAATCAGTTTATTCATCAGTTA	2820	
Qy	2830	TCAAATGCGATAGACAGTAGACGAATGCAGGATACAAATGTATGTGGTAAGGAGGATTTG	2889	
Db	2821	TCAAATGCGATAGACAGTAGACGAATGCAGGATACAAATGTATGTGGTAAGGAGGATTTG	2880	
Qy	2890	GAGATCATACTTCTCTGAATGTCCAGTTGGAAAAGATGTAGAGTTGTTGCCAAGACTCTC	2949	
Db	2881	GAGATCATACTTCTCTGAATGTCCAGTTGGAAAAGATGTAGAGTTGTTGCCAAGACTCTC	2940	

Qy	2950	ACTTCAGTATACAAACCATTAAGGAAGACCTTTGCCACTTTAGAACATTTGTACAAAAAG	3009
Db	2941	ACTTCAGTATACAAACCATTAAGGAAGACCTTTGCCACTTTAGAACATTTGTACAAAAAG	3000
Qy	3010	AACAGTGTGACTTCTCAAAATTCATTAAATGTCACAGCAGTAGAAATAAGAAACATTATTG	3069
Db	3001	AACAGTGTGACTTCTCAAAATTCATTAAATGTCACAGCAGTAGAAATAAGAAACATTATTG	3060
Qy	3070	AAAAAGTAAATGTTCTCTCGGAAATAACACTAAAAAGAAAAACATCAAAAGAACTACTGT	3129
Db	3061	AAAAAGTAAATGTTCTCTCGGAAATAACACTAAAAAGAAAAACATCAAAAGAACTACTGT	3120
Qy	3130	CTTTAAAAAATGAATATGAAGSTAAACTTGACGGACTAATAAAGGAACTGAAGAGAATG	3189
Db	3121	CTTTAAAAAATGAATATGAAGSTAAACTTGACGGACTAATAAAGGAACTGAAGAGAATG	3180
Qy	3190	AAAACAAAATTAATAAATGAAGGGAGAGTTAGTATGCCCTTGAGGAGGTTTTACAAAATA	3249
Db	3181	AAAACAAAATTAATAAATGAAGGGAGAGTTAGTATGCCCTTGAGGAGGTTTTACAAAATA	3240
Qy	3250	AGATAATGAATTTGCTTTGGTTAAACATGAAAAAGAGCTGTAACTGCGCTGCAGAAATG	3309
Db	3241	AGATAATGAATTTGCTTTGGTTAAACATGAAAAAGAGCTGTAACTGCGCTGCAGAAATG	3300
Qy	3310	AAAAGGATCAGAAAGTTGTTAGAGATGAAAAATATAATGCACCTCAAAATTTGTGAATTA	3369
Db	3301	AAAAGGATCAGAAAGTTGTTAGAGATGAAAAATATAATGCACCTCAAAATTTGTGAATTA	3360
Qy	3370	AAGAACTGAAGCAGTACAGAGAAATAGTGTTTAGAAGACTTAAAAAGCTCCATGTTGAAA	3429
Db	3361	AAGAACTGAAGCAGTACAGAGAAATAGTGTTTAGAAGACTTAAAAAGCTCCATGTTGAAA	3420
Qy	3430	ATGATGAGAAGTTTACAGTTATTGAGGGCAGAACTTCAGTCCTTGAGGCAAAAGTCATCTAA	3489
Db	3421	ATGATGAGAAGTTTACAGTTATTGAGGGCAGAACTTCAGTCCTTGAGGCAAAAGTCATCTAA	3480
Qy	3490	AGGAATTAGAGGACACACTTCAGGTTAGGCACATACAAGAGTTTGAGAAGGTTATGACAG	3549
Db	3481	AGGAATTAGAGGACACACTTCAGGTTAGGCACATACAAGAGTTTGAGAAGGTTATGACAG	3540
Qy	3550	ACCACAGAGTTTCTTTGGAGGAAATTAATAAGGAAATCAACAATAATTAATCAAAATAC	3609
Db	3541	ACCACAGAGTTTCTTTGGAGGAAATTAATAAGGAAATCAACAATAATTAATCAAAATAC	3600
Qy	3610	AAGAATCTCATGCTGMAAATTATCCAGGAAAAAGAAAAACAGTTACAGGAATTAATACTCA	3669
Db	3601	AAGAATCTCATGCTGMAAATTATCCAGGAAAAAGAAAAACAGTTACAGGAATTAATACTCA	3660
Qy	3670	AGGTTTCTGATTTTGTGAGACAGAGATGCAAGTTAGAGGTTGAACTTCGGTTGAAGGAAG	3729
Db	3661	AGGTTTCTGATTTTGTGAGACAGAGATGCAAGTTAGAGGTTGAACTTCGGTTGAAGGAAG	3720
Qy	3730	CAGAACTGATGAAATAAAAATTTTGTCTGGAAGAAAGCAGAGCCGACAGAGAGACCT	3789
Db	3721	CAGAACTGATGAAATAAAAATTTTGTCTGGAAGAAAGCAGAGCCGACAGAGAGACCT	3780
Qy	3790	TGAAATCTCTCTTTGAAACAGAGACAGAAAAATTTGAGAACAGAAATTAGTAATACTCAACC	3849
Db	3781	TGAAATCTCTCTTTGAAACAGAGACAGAAAAATTTGAGAACAGAAATTAGTAATACTCAACC	3840
Qy	3850	AAAGATTACAGGATAATAATGAAATATACAGSTGGGCTTAGCAGAGCTAAGAACTTTAA	3909
Db	3841	AAAGATTACAGGATAATAATGAAATATACAGSTGGGCTTAGCAGAGCTAAGAACTTTAA	3900
Qy	3910	TGACAAATTGAAAAGATCAGCGTATTTCCGAGTTAATTAGTAGACATGAAGAAGATCTA	3969
Db	3901	TGACAAATTGAAAAGATCAGCGTATTTCCGAGTTAATTAGTAGACATGAAGAAGATCTA	3960

Qy	13970	ATCATGTAAGCTGTAATTAAACAAGTACACTCTTTGCATACCAAGCATTTGAAATAG	4029
Db	13961	ATATACCTTAAGCTGTAATTAAACAAGTACACTCTTTGCATACCAAGCATTTGAAATAG	4020
Qy	4030	AAAAAAACCTTAAGAGACAAATATTGAACTGCAGAGTAAATTTGGATTCAGATTGAGTG	4089
Db	4021	AAAAAAACCTTAAGAGACAAATATTGAACTGCAGAGTAAATTTGGATTCAGATTGAGTG	4080
Qy	4090	CTCTTGAAAGACAAAAGATGAAAAAATTACCCAACAGAAGAAATACGAAGCTATTA	4149
Db	4081	CTCTTGAAAGACAAAAGATGAAAAAATTACCCAACAGAAGAAATACGAAGCTATTA	4140
Qy	4150	TCCAGAACCTTGAGAAAGACAGACAAAAATTTGGTCAGACGCCAGGAGCAAGACAGAGAAC	4209
Db	4141	TCCAGAACCTTGAGAAAGACAGACAAAAATTTGGTCAGACGCCAGGAGCAAGACAGAGAAC	4200
Qy	4210	AGTTAATTCAGAGCTTAATTTGTGAAAAGATGAAGCTATTTCAGACTGCCCTAAAAGAAT	4269
Db	4201	AGTTAATTCAGAGCTTAATTTGTGAAAAGATGAAGCTATTTCAGACTGCCCTAAAAGAAT	4260
Qy	4270	TTAAATTTGGAGAGAGAAGTTGTTTGAGAAAGAGTATTAGAAAAAGTTAAACATCTTGAGA	4329
Db	4261	TTAAATTTGGAGAGAGAAGTTGTTTGAGAAAGAGTATTAGAAAAAGTTAAACATCTTGAGA	4320
Qy	4330	ATCAAAATAGCAAAAAGTCTCGCCATTGACTCTACAGAGGAGATTCTTCAAGCTTAGTTG	4389
Db	4321	ATCAAAATAGCAAAAAGTCTCGCCATTGACTCTACAGAGGAGATTCTTCAAGCTTAGTTG	4380
Qy	4390	CTGAACTTCAAGAAAAGCTTCAGAGAAGAAAGCTTAAGTTTCTAGAACACTTGAAGAGC	4449
Db	4381	CTGAACTTCAAGAAAAGCTTCAGAGAAGAAAGCTTAAGTTTCTAGAACACTTGAAGAGC	4440
Qy	4450	AGAAAAAGAGAGAAATGAGAAATGCAAAATTTGGAACATCTTTGATTCGGGAACAC	4509
Db	4441	AGAAAAAGAGAGAAATGAGAAATGCAAAATTTGGAACATCTTTGATTCGGGAACAC	4500
Qy	4510	AGACCAATTTTAACTCTGTTTTACAAAGAGAGAAATGAGAAAGAAAAATAATAAATG	4569
Db	4501	AGACCAATTTTAACTCTGTTTTACAAAGAGAGAAATGAGAAAGAAAAATAATAAATG	4560
Qy	4570	ATCTTAGTAGTAAGTTGAAAAGTACAAATGCAGCAACAGAGCGGATAAAGATTGTATAG	4629
Db	4561	ATCTTAGTAGTAAGTTGAAAAGTACAAATGCAGCAACAGAGCGGATAAAGATTGTATAG	4620
Qy	4630	AGTCACTTTCTGAAGATCGAGCTCGTTTTGCTTGAGGAAAAAGAAAAGCTTGAGAAGAGAG	4689
Db	4621	AGTCACTTTCTGAAGATCGAGCTCGTTTTGCTTGAGGAAAAAGAAAAGCTTGAGAAGAGAG	4680
Qy	4680	TCAGTAAGTTGGCGAGTAGCAGSTTTTGTCTCTCACCATATGTAGTCTACAGCCCGAGAAC	4749
Db	4681	TCAGTAAGTTGGCGAGTAGCAGSTTTTGTCTCTCACCATATGTAGTCTACAGCCCGAGAAC	4740
Qy	4750	TTTATGGAGTTGTGCACTGAACTCCACGGTGAATCAGATAGATCCGCTGTGGAAACAG	4809
Db	4741	TTTATGGAGTTGTGCACTGAACTCCACGGTGAATCAGATAGATCCGCTGTGGAAACAG	4800
Qy	4810	CAGATGAAGAGAGAGTGGATTTCAGCAATGAGACAAGCATGATGTCTGTACAGAAAAATA	4869
Db	4801	CAGATGAAGAGAGAGTGGATTTCAGCAATGAGACAAGCATGATGTCTGTACAGAAAAATA	4860
Qy	4870	TTCATATGTTGCTTGAGAAAAACAGCGGATAATGCTGTTAGAACAACTTGCATTGTA	4929
Db	4861	TTCATATGTTGCTTGAGAAAAACAGCGGATAATGCTGTTAGAACAACTTGCATTGTA	4920
Qy	4930	AGAGAGAGAAAAATAAGCGTTAAATCAAGAGCTGATGTCTCAGAGCATGTCTTCAGTAT	4989

Db	4921	AAGAAGAAGAAAAATAAACGGTTAAATCAAAGACTGATGTCTCAGAGCATGTCTTCAGTAT	4980
Qy	4990	CTTCAAGGCATTCTGAAAAATAGCTATTAGAGATTTTCAGGTGGGAGATTTGGTACTCA	5049
Db	4981	CTTCAAGGCATTCTGAAAAATAGCTATTAGAGATTTTCAGGTGGGAGATTTGGTACTCA	5040
Qy	5050	TCATCCTAGACGAAACGCCATGACAAATTATGTGTTATTACTGTTAGTCCTACTTTATATTT	5109
Db	5041	TCATCCTAGACGAAACGCCATGACAAATTATGTGTTATTACTGTTAGTCCTACTTTATATTT	5100
Qy	5110	TTCTACATTTCAGAGTCTCTACCTGCGCTGGATCTCAAACAGGTGAGGGTGCTTCAGGTG	5169
Db	5101	TTCTACATTTCAGAGTCTCTACCTGCGCTGGATCTCAAACCA-----GCTTCAGGTG	5151
Qy	5170	CATCTAGAAGACCCCTGGGTACTTGGAAAAAGTAATGAAAAAGAACTGTCAAGCCAAAA	5229
Db	5152	CATCTAGAAGACCCCTGGGTACTCGGAAAAAGTAATGAAAAAGAACTGTCAAGCCAAAA	5211
Qy	5230	AGGCACAAAACAGATTTAAAGTTCCTTTGGGGACAAAGTTTTCAGAGTGAAGCCGTAT	5289
Db	5212	AGGCACAAAACAGATTTAAAGTTCCTTTGGGGACAAAGTTTTCAGAGTGAAGCCGTAT	5271
Qy	5290	CATGGAATAGAAAGTATACTTATGGACAAAATTAATACATTTCTATGACATTTTTCCT	5349
Db	5272	CATGGAATAGAAAGTATACTTATGGACAAAATTAATACATTTCTATGACATTTTTCCT	5331
Qy	5350	GATTTGTCTGTCAGTGTCTCATTCACCTCCAAAAACAGCAGGCCATCTTTTTATGCAAA	5409
Db	5332	GATTTGTCTGTCAGTGTCTCATTCACCTCCAAAAACAGCAGGCCATCTTTTTATGCAAA	5391
Qy	5410	AGTCAGCGTGACAAATATACCTTCACTGGTGTACATCGTTTTACTTTTTAACTGGCTCATTT	5469
Db	5392	AGTCAGCGTGACAAATATACCTTCACTGGTGTACATCGTTTTACTTTTTAACTGGCTCATTT	5451
Qy	5470	TAGGAATAATAAATTCACAGAACTCCTGGCTGAAATAAAAATGGTTTTTGGTTTTGGTT	5529
Db	5452	TAGGAATAATAAATTCACAGAACTCCTGGCTGAAATAAAAATGGTTTTTGGTTTTGGTT	5511
Qy	5530	TTTTTTTTTACCAGACAACCTCTAGAAATGCGGACCAAACTACTTTCATTTTCTCAAAAGG	5589
Db	5512	TTTTTTTTTACCAGACAACCTCTAGAAATGCGGACCAAACTACTTTCATTTTCTCAAAAGG	5571
Qy	5590	CATACCTTGTGCATTGTGGCTTATGATGAGCCATATTAATTCGCTGTAAATATACACTA	5649
Db	5572	CATACCTTGTGCATTGTGGCTTATGATGAGCCATATTAATTCGCTGTAAATATACACTA	5631
Qy	5650	GCTTGAACCTTAGATGTTAAATGTTATTATTACCAGCATTGTGCTTTTTGTGAAATCAGTA	5709
Db	5632	GCTTGAACCTTAGATGTTAAATGTTATTATTACCAGCATTGTGCTTTTTGTGAAATCAGTA	5691
Qy	5710	TCAGAACTACTTGCACCTTTTAACACATCTTTATATAAAATGTATAAATTTATCAGAACTA	5769
Db	5692	TCAGAACTACTTGCACCTTTTAACACATCTTTATATAAAATGTATAAATTTATCAGAACTA	5751
Qy	5770	TTAAAAATAAGAGGAGTGTATTGCGATGCTGATTAATCATTTTGAGTTTGGCTCAGTAGAT	5829
Db	5752	TTAAAAATAAGAGGAGTGTATTGCGATGCTGATTAATCATTTTGAGTTTGGCTCAGTAGAT	5811
Qy	5830	ACTAAAGCAAAATGTTTCAGTTTTTTTAAATGCGCTTTGATGTTTCAAAAAAAGGA	5889
Db	5812	ACTAAAGCAAAATGTTTCAGTTTTTTTAAATGCGCTTTGATGTTTCAAAAAAAGGA	5871
Qy	5890	ACTGTAATTTGATTGACTGATTTTAAGATCAGCCATAAGTAATCAGCAATCTTCAAAAGC	5949
Db	5872	ACTGTAATTTGATTGACTGATTTTAAGATCAGCCATAAGTAATCAGCAATCTTCAAAAGC	5931
Qy	5950	ACTTTTCAGTGGATTGGTCATCTGGGTTCTAAAGGGAAGAGTCGTGCTACTAACCATTTTC	6009

```

Db      5932  |||||
ACTTTCAGTGGATTGGTCATCTGGTCTTAAAGGGAAGAGTCTGGTCTACTAACCATTTTC 5991

Qy      6010  AAATCAGACTCAAAACCTTCCCAATCTTATGACTCTAGCAATAATCATATTGATGAAA 6069
|||||

Db      5992  AAATCAGACTCAAAACCTTCCCAATCTTATGACTCTAGCAATAATCATATTGATGAAA 6051
|||||

Qy      6070  TCGTAATTCATGGTTGAGTTTCAGAACAAAGATATTCAATGGCAATTAACATTAGAG 6129
|||||

Db      6052  TCGTAATTCATGGTTGAGTTTCAGAACAAAGATATTCAATGGCAATTAACATTAGAG 6111
|||||

Qy      6130  GTCATTTAAATAACAAAATATTGTATTGTAAAAGAACTGTACAATTTTAAAAAATAAAG 6189
|||||

Db      6112  GTCATTTAAATAACAAAATATTGTATTGTAAAAGAACTGTACAATTTTAAAAAATAAAG 6171
|||||

Qy      6190  ATTTGAACCTGTAAATGTGTGTGCGCTTTTAAAGAAAGATACATTTTAAATATATTGAGT 6249
|||||

Db      6172  ATTTGAACCTGTAAATGTGTGTGCGCTTTTAAAGAAAGATACATTTTAAATATATTGAGT 6231
|||||

Qy      6250  GATTGCTGGGAAGTGTGAAAATATTGTATGTATCATATCAAAAGAGAAACATGTTTATTA 6309
|||||

Db      6232  GATTGCTGGGAAGTGTGAAAATATTGTATGTATCATATCAAAAGAGAAACATGTTTATTA 6291
|||||

Qy      6310  CAAAAATGTTCTTTAACTATATACATATGTAAACAGGGTAAACAGTGTATGTAGATAAGAA 6369
|||||

Db      6292  CAAAAATGTTCTTTAACTATATACATATGTAAACAGGGTAAACAGTGTATGTAGATAAGAA 6351
|||||

Qy      6370  TTGTTAAACTAGATCTTTAGAGAAAGTGGCAATTGAGCAAAAGTATTATTAATGAGTTAGT 6429
|||||

Db      6352  TTGTTAAACTAGATCTTTAGAGAAAGTGGCAATTGAGCAAAAGTATTATTAATGAGTTAGT 6411
|||||

Qy      6430  TGAGTTGGATGAGAAATTGTTTGAGGTTTGTGCTAGAGAACAAATATAAAATATCTTT 6489
|||||

Db      6412  TGAGTTGGATGAGAAATTGTTTGAGGTTTGTGCTAGAGAACAAATATAAAATATCTTT 6471
|||||

Qy      6490  TTCAGAAAAATATTTAATTTCTTCATAAAAAAAGTTAAATTTTTTAAATATGTATAT 6549
|||||

Db      6472  TTCAGAAAAATATTTAATTTCTTCATAAAAAAAGTTAAATTTTTTAAATATGTATAT 6531
|||||

Qy      6550  CTAATAGTACAAAAATGGAATAAACATCATAGTGTATAGAAAACGTAATTTGACAAGTTAA 6609
|||||

Db      6532  CTAATAGTACAAAAATGGAATAAACATCATAGTGTATAGAAAACGTAATTTGACAAGTTAA 6591
|||||

Qy      6610  TGAATAAATGAACAAATGATTTC 6632
|||||

Db      6592  TGAATAAATGAACAAATGATTTC 6614
|||||

```

LOCUS	D86958	6614 bp	mRNA	linear	PRI 22-AUG-1996
DEFINITION	Human male myeloblast mRNA for KIAA0203 protein, complete cds.				
ACCESSION	D86958				
VERSION	D86958 GI:1503989				
KEYWORDS	KIAA0203 protein.				
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				
	Eukaryota; Eukaryota; Eukaryota; Metazoa; Chordata;				
	Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
REFERENCE	1 (bases 1 to 6614)				
AUTHORS	Nomura, N.				
TITLE	Direct Submission				
JOURNAL	Submitted (02-AUG-1996) Nobuo Nomura, Kazusa DNA Research Institute; 1532-3 Yanauchino, Kisarazu, Chiba 292, Japan (E-mail:cdnainfo@kazusa.or.jp, Tel:0483-52-3930, Fax:0483-52-3931)				
REFERENCE	2 (bases 1 to 6614)				
AUTHORS	Nagase, T., Seki, N., Ishikawa, K., Ohara, O. and Nomura, N.				
TITLE	Prediction of the coding sequences of unidentified human genes. VI. The coding sequences of 80 new genes (KIAA 0201 - KIAA 0280)				

deduced by analysis of cDNA clones from human cell line KG-1 and brain

JOURNAL Unpublished (1996)

FEATURES Location/Qualifiers

source 1..6614

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/chromosome="8"

/sex="male"

/cell_line="KG-1"

/cell_type="myeloblast"

5'UTR 1..515

gene 516..5291

/gene="K1AA0203"

CDS 516..5291

/gene="K1AA0203"

/note="The K1AA0203 protein has similarity to mouse CCL1."

/citation=[2]

/codon_start=1

/product="K1AA0203 protein"

/protein_id="I50390"

/db_xref="GI:I50390"

/translation="MKLLVFLVNTGTTTLTFDTELTVQTVADLKHAIQSKYKIAIQHQV
LVVNGGECMAADRRCVCTYSAGTDNPFILFNKEMILCDRPPAIPKTTFTSTENDMEIKV
EESLMPAVFHTVASTQQLAEMYEYAKKLCSPCEGLVHDEHLQHQGWAAIMANLEDC
SNSYQKLLPFKFSIYSNYLQSIEDIKILKTLHGTAVSMVAKIPLLECLTRHSYRECLG
RLDSLPEHDESEKAEATKRSFTELVSPDMPTTNSLLTSPKSPVEHVSPTDAEASGK
BIRESCQSTVHQDDETTIDTKDGDLPFFNVSLDLWINVQDRPNDESVLRKCPDMSMR
LDPRIIRPFIACRQGTAKLDNQNMKAIKGELEDRYALDQMIAASCGRLVNEQKELAQG
FLANQKRAENLKDASVLPDLCLSHANQIMILQNHRLKLLDIKQCTTAKQELANNLHV
RLKWCFCVPMHADQDGEKLQALLRLVIELLRVKIVLEALSTVPMYCLAVVEVVRKM
FIKHRYEWAGALVQDKGRLEYAEKSKRESFGKLFKRSFLANALFGLDWPPEFCTQK
PRKFDCELPDISLKDQLQFLQSPFSEVQVFLRVFLICDFEPLHQHVLALHNLVKAAGS
LDMSGTITDLLGSEQRAVSQTSFQSAASSFRMESTAGTITTTTSFRTPTLVQDPLCP
ANCELEELSFDSDIAHTFDPEIIEHNIEQTTHGVSLLDLSIAESPSDDMSAVNEFV
IEENLISSEPTISDQSPHEMMVESLYSSVINAIDSRMGQDPTNCGKEPDPDHTSLNVL
ERCRVVAQDSHFSTQTIKEDELCHERTFVQKQDQFNSGLKCTAVEIRNIIEKVKSGLE
ITLKEKHQKELLKSNVEYEGKLDGLIKETEENENKIKKLKGLVCLLEVLQKNDNEFA
LVKHEKEAVICLQNEKQDKLEMEMNHSQNCIEKELQSRFIVLELDKLLHVNDEK
IQLLRAELQSLQESHLEEDTLQVAHIQEFKVMTHDRVSVLEELKKNQOIINQIQE
SHAEITIQEKELQELKLVSDTRCKLVEVLALEKAEATDEIKILLLESRAQKET
LKSLLEQETENLRTEISKLNQKIQNDNNENYQVGLAELATLMTIEKDQCSIELISRHE
ESNLIKAEINKVTSLHNQAFIEKNLKEQIIEQLQSKLSELSALERQKDEKITQEBEK
YEALIQNLKEDRKQIVSVSQDQDRLQIKNLCKDEATQALKEPKLREVEVEKELLE
KVKHLENQIAKSPALDSTRGSSSVIAELQEKLEKAKFLQLEEQEKKRKNEMQNV
RTSLTAQQTNNFNTVLTRKKMKKENIINDLSKLKSTMQQERDKOLLSLESDRRL
LEBKKLLEBEVSRLRSSFPVSPYVATAPELYGACAPELPGESDRSABVTADEGRVDS
AMETSMSSVQENIHLSEBKQRIMLERTILQKBEENKRLNQLRMSQMSVSSRHS
KIALRDFQGVGLVILLDERHONVYLFVSPPLYFLHSELPALDLKPASGASRFPW
LGKVMKEKIQAKKAQNKRFVPLGTGFYRVKVASWKKV"
5292..6614

5'UTR

ORIGIN

1	aaacaaacaa	gcgcgcgcgc	tgctgcgcgc	cctgcgcgcg	cctgcgcggt	cctgcagaat
61	oococagctg	cctgcgcgcgc	tcgctgcctga	caggcgcgcg	cctctgcctc	oocgcgcgcg
121	gaococagagc	cgaggggcgc	gctgcgcgcgc	tgctgcgcgc	ggacococctc	ctgcgcctca
181	gaagtctcggg	ccgcgcgcgc	cgagcgcgcgc	ggacgcgcgc	ggttgtgtgc	gcttagcggt
241	gcggaatggg	cggttgtgtga	cgcgtgcgcga	ggactaggcg	gcgcgcgcga	atggtgcgcg
301	gggtgcgtgc	ctctgcctgc	gcgcgcgcgc	aaggagggag	cgttgcgcgt	ttctgcagtt
361	taacacagtaa	tgccaatccag	ttgcacatct	caagcacaagc	aaacataaagc	cagttttaat
421	ctactctttta	agaaaagtgg	tagtctcttt	cacagtcgct	gacgttaactg	tatcacaggg
481	tgaggtataa	gctcacagaa	ttcagataaa	tcatcatgaa	gttatatgta	ttctctggtta
541	acactggaaac	tactctaaaca	tttgacacgtg	aaactacagc	gcacaaactgtg	cgacagcctta
601	agcctgccat	tcaaaagcaaa	tacaagaattg	ctatttcaaca	ccaggtgctg	gttgctcaatg
661	gagggagaatg	catggtctgca	gatcgagaag	tggttgactca	cagtgctggg	acggatcacaa
721	atccaatttt	ttcttttaaac	aaagaatgta	tcttatgtga	tcgtccacct	cttatctcta
781	aaactacctt	ttcgacagaa	aatgacatgg	aaataaaagt	tgagaatct	gcttagatgc

Art Unit: 1642

841 ctgcagtttt tcaatctgtt gottccaagga caacagcttgc attggaaatg tatgaagttg
 901 ccaagaaaact ttgtcttctt tgtgaagctc ttgtacatga tgaacatctt caacacccaag
 961 gctgggtctgc aatcaatggcc aacotggagg acgtgtccaa ttcatcaaaa ttcatcaaaa
 1021 tcaagtttga aagatttat tcaaatatcc tgcctacatg tgcgaagatc aagttaaaac
 1081 ttactctatt agcaactctg gtttccatga tgcgcaagat tccactctgt gattgctaaa
 1141 ccaagcaatag ttacaagaaa tgtttggaaa gaotggatct ttactcgtaa catgaagact
 1201 cagaaaaaagc tgaagcagaa agatccaact aaotggtgct ctctcctgat atcctatgaa
 1261 caactaaocga atcttttgtta aotcatttcc ccaagtcagt ggaacatgtg tgcocagata
 1321 ccgcagatgac tgaaaagtgc aaagaataat ggaatctctg tcaaaagtact gttcctcagc
 1381 aagatgaaac tcaagtatgac actaaagatg tgatctcgcg ctcttttaat gttctcttgg
 1441 taagctggat aaatgttcaa gatagaccta atgatgtgga atctttgttc aggaagtgtg
 1501 ttgattctat gagaagcgtt gatccaaagga ttattcgaac atttatagca gaatgcgcgc
 1561 aaaaatttgc caaacttgat aatcaagaata tgaagcccat taaaggactt gaagatcgcc
 1621 ctactgcctct ggaaccaatg attgctagct gtggccgact ggtgaatgaa cagaaaagac
 1681 ttgctcaggg atttttagct aatcaagaag gagctgaaaa cttaaaagat gccatctgat
 1741 taactgattt atgcctgagt caagcgaatc agttgatgat tatgttgcaa aatcatagaa
 1801 aactgtttaga tattaagcag aagttgaaca ctgcgaacaa agaactagca aataaotcct
 1861 atgtcagact gaagtgggtt tgottttgaa tgcctcagc tgatccaagt ggaagaaagt
 1921 tacaagcttt gctcgcctcc gtaatagagc tgttagaaga agtcaaaatt gtgtgaagct
 1981 ttagtacaagt tcootcagatg taactgttag ctgttgttga ggttgtgaag agaaatgct
 2041 tcaataaaca ctacagaggag ttgctgtgtg cttaactcaa agatgagaag agattatatg
 2101 aagcagaaaa atcaaaaaag gaatcctttg ggaatatatt taagaaagctc tttttaagaa
 2161 attcgtctgt ttggggcact gaactcctgc cccctctatt ttgtactcaa aagcctcgaa
 2221 agtttgactg tgaacttcca gatatttcat taaaagattt acagttttct caatcatttt
 2281 tgccttcagg agttcagcca ttcootcagg ttcootact ttgtgacttt gaaotctcac
 2341 accagactgt acttgctcta cataatttgg taaaagcagc acaaaagttt gatgaatagt
 2401 ccaagaccat tacaagctta ctgagtgaa aaaaagcact tgtgagtcag aactccccac
 2461 agtctgcttc ttcaaccaag attgaaaata cagcaggaaat tacaactact acctcacoga
 2521 gaaotcctcc accaactgaat gttcaggatc ccttatgtcc tgcagtttgt ctttagaag
 2581 aattatctcc agatagtatt gatgcacata cgtttgatt ttgaactatt cccactccaa
 2641 acatagaaca gactattcac caagtttact tagacttga ttcatagca ttcaagctcg
 2701 aatcagattt tatgtctgct gtgaatgagt ttgtaataga agaaaaattg tgcctccta
 2761 atcctataag ttatccaaaa agcccaagaa tgaatggtga atcaacttat tcatcagta
 2821 tcaatgcgat agacagtaga cgaatgcagg atacaaaatg atgtggttaag gaagattttg
 2881 gagatcatac ttctctgaat gtccagttgg aaagatgtag agtttgttgc caagactctc
 2941 acttcagtat acaaacactt aaggaagacc ttgycacat tagaacaatt gtcaaaaaag
 3001 aacagtgtga ctctcaaat tcaataaact gtacagcagt agaatagaag aacattatgt
 3061 aaaaagttaa atgtctctg gaataaacc taaaaagaaa acatcaaaaa gaactcgtg
 3121 ctttaaaaaa tgaatatgaa ggttaaacctg accgactaat aaaaagaaot cagaagaagt
 3181 aaaaacaaaat taaaaaattg aagggagagt tagtatgct tgaaggagtt ttacaaaata
 3241 aagtaaatga atttgctttg gttaaaactg aaaaagaagc tgtaactcgc ctgcagaagt
 3301 aaaaagatca gaagtttgtta gaagtggaaa atataatga ctctcaaat ttgtgaata
 3361 aagaactgaa cgaatcaaga gaatatgtgt tagaagactt aaaaagctc catgttgaaa
 3421 atgtatgaaa gttacagtta ttgagggcag aaotcagct ctggagcaa catctcttaa
 3481 aggaattaga ggaaccaact caggtttagc acatcaacga gtttgagaag gttatgacag
 3541 acccagaggt ttctttggag gaattaaaaa aggaacaaa ccaataatt aatcaaatc
 3601 aagaattcca tgctgaaatt atccagagaaa aagaaaaaca gttacagaaa ttaaaactca
 3661 agttttctga ttgttcagac acgaatgca atttagaggt tgaacttgcg ttgaagaaag
 3721 cagaaactga tgaataaaaa attttgctgg aagaagcag agccagcag aagaagact
 3781 tgaatatctc ttctgaacca gagacaagaa atttgagac aaaaatagt aaactcaac
 3841 aaaaagattca ggaataataa gaaaatttcc agtggtggct agcagagcta agaaatttaa
 3901 tgaacattga aaaaagatcg tgaatttccg agttaatag tagacatgaa gaagaactca
 3961 atatacttga agctgagata ataatgtgca ctctcttgc tacaacaga ttgtgaatg
 4021 aaaaaaacct aaagacaaa ataatgtgac tgcagagtaa atgttgctca gaattgagt
 4081 ctcttgaaag ccaaaaagat gaaaaaata ccaacaaag agaaaatac gaagattata
 4141 tccagaaact tgaagaaagc agacaaaaat tggctcagcag ccaggagcaa gacagagac
 4201 agttaattca gaagottaat tgtgaaaaag atgaagctat tccagactgc ctaaaagat
 4261 taaatttggg gagagaagt gttagaaaag agttattaga aaaagtttaa catcttga
 4321 atcaaatagc aaaaagctct gccattgact ctaccagagc agattctcca gatattgtg
 4381 ctgaacttca agaaaagctt caggaagaaa aagctaaagt totagaacaa cttgaagagc
 4441 agaaaaaaag aaagatgaa gaaatgcaaa atgttcgaac atctttgat gctgcaaac
 4501 agacaaattt taactcgtgt ttaaccaag agaaaatgag aaaaagaaac ataatatag
 4561 atctttagtga taagttgaaa agtacaactgc agcaacaaa acgggataaa gatttgtag
 4621 agtcaacttc tgaagatcga cgtcgtttgc ttgagaaaa gaaaaagct gaagagaag
 4681 tcaatgaagt gcgcagtgc agttttgttc ctaccacaa tgtagtcca gccccaagac
 4741 tttagagagc ttgtgcactc gaaactccag gtgaatcaga tagatcctgt gtggaaaacg
 4801 cagatgaagg aagagtggtt tcaagcaatg acacaagcat gatgtctcta caagaaaata


Art Unit: 1642

```

4861 ttcatatggt gtctgaagaa aaacagoggg taatgtgttt agaagcaaca ttgcgaattga
4921 aagagaagaaga aaataaaagg ttaaatcaaa gaotgagtgt tcagagcagt ttcttcagtat
4961 ctccaaggca ttctgaaaag atagctatta ggaattttca ggtggggagat ttggtactca
5041 tcatctcaga cgaacacgat gaacattag ttgtatttgc ttgtatgctc actttatatt
5101 ttctaacttc agattctcta cctgcctctg atctcaaacg agcttcaggt gcatctagaa
5161 gacccctgggt actcggaaaa gtaattgaaa aagaatactg tcaagccaaa aagggcaaaa
5221 acaattttaa agttcccttt gggaacaaat ttacaagat gaagccgtta tcatggaata
5281 aaaaagtata acttatggac aaatttaata catctataga catttttttc tgattttgtc
5341 tgcagtgtctc attcatcact ccaaaaaaacg caggccatct ttttatgcaa aagtcagcgt
5401 gcaactatac ttcaactggg ttacatggtt acitttttac ttggttcat ttaggaaataa
5461 taattatcat agaatccctg gtggaattaa aatggttttt gtttttttgt tttttttttt
5521 aaccagacaa ctctagaaat ggggaacaaa ctacttcatt ttctcaagg gcataccctg
5581 tgcattgtgg cttatgatga gccatattaa ttgcctgta aatatacact agotggaact
5641 tagatgttaa atgttattat taacagcatt tgtccctttg tgaaatcagt atcagaatac
5701 ttgcactctt taacacattc ttataaaatt gtataaatta ttccagaacta tttaaaaataa
5761 aagagagtggt tattgcctgc tgataatcat tttagatttg cctcagtaga tactaaaaga
5821 aattgtttca gtttttttaa atgccccttg atgtttcaaa aaaaaaaagg aactgtaatt
5881 tgattgactg attttaagat cagccataag taatcagcaa tttcaaaag caacttcaat
5941 ggatttgtca tctgggttct aaagggaaga gtctgtgcta ctacccattt caaatgcaga
6001 ctcaaacctt ccaacatct ttatgactct agaatataca tactgtgaa atcgttaattc
6061 atgtgtgaat ttcaagacaa aagatattca ttgcacata accattttga ggtcatttta
6121 ataacaaaat attgtattgt aaagaacact taacatttta aaacaaataa gatttgaac
6181 tgaataatgt ttgtcccttt aaagaagcat acatttttaa tatatttga tgatttgtgg
6241 gaagtgtgaa aattattgta ttgtatcat caaagagaaa catgtttatt acaaaaatgt
6301 tctttaaacta tatactatgt aacagggtaa acagtgttat gtagaataga attgtgtaaa
6361 ctatgattctt agagaattgt ccatgagca aagtatttta aatgatttag ttgattgtga
6421 ttgagaattgt ttgagttttg ttgtagaga acaataataa aataattctt ttccagaaaa
6481 tattttaatt ctctcaaaaa ataagttaaa tattttttta aatagtata tctaatagta
6541 caaaatggaa taacatcat agtgataga aaactgaatt tgacaagtta atgaataaat
6601 gaacaaatga ttct

```

//

 **Blast 2 Sequences results**

[PubMed](#)
[Entrez](#)
[BLAST](#)
[OMIM](#)
[Taxonomy](#)
[Structure](#)

BLAST 2 SEQUENCES RESULTS VERSION BLASTP 2.2.18 [Mar-02-2008]

Matrix: gap open: gap extension:

x_dropoff: expect: wordsize: Filter: ☐ View option:

Masking character option: Masking color option:

☐ Show CDS translation

Sequence 1: gi|40788906|KIAA0203 [Homo sapiens]

Length = 1593 (1 .. 1593)

Sequence 2: gi|119607126|RB1-inducible coiled-coil 1, isoform CRA_b [Homo sapiens]

>gi|168272926|dbj|BAG10302.1| RB1-inducible coiled-coil protein 1 [synthetic construct]

Sbjct	541	LFNRKSLRNKFLRGLSDWPPSPCTQKPRKFDCELPDI SLKDQLQLQSPSPSPSPVQFFLRVP LFNRKSLRNKFLRGLSDWPPSPCTQKPRKFDCELPDI SLKDQLQLQSPSPSPSPVQFFLRVP	600
Query	603	LLCDPEPLHQHVLALHNLVKAAGSLDMSQTTIDLLSEOKASVSQTSFQASSSFRMESTA LLCDPEPLHQHVLALHNLVKAAGSLDMSQTTIDLLSEOKASVSQTSFQASSSFRMESTA	662
Sbjct	601	LLCDPEPLHQHVLALHNLVKAAGSLDMSQTTIDLLSEOKASVSQTSFQASSSFRMESTA LLCDPEPLHQHVLALHNLVKAAGSLDMSQTTIDLLSEOKASVSQTSFQASSSFRMESTA	660
Query	663	GITTTTSPRTPPPLTVQDPLCPAVCPLEELSPDSIDAHTFDFETIHPHNIHQTHQVSLD GITTTTSPRTPPPLTVQDPLCPAVCPLEELSPDSIDAHTFDFETIHPHNIHQTHQVSLD	722
Sbjct	661	GITTTTSPRTPPPLTVQDPLCPAVCPLEELSPDSIDAHTFDFETIHPHNIHQTHQVSLD GITTTTSPRTPPPLTVQDPLCPAVCPLEELSPDSIDAHTFDFETIHPHNIHQTHQVSLD	720
Query	723	LDLSLSPSPSPDFMSAVNEFVIRENLSSPNFISDPQSPMMVSELYSSVINAIDSRMQDT LDLSLSPSPSPDFMSAVNEFVIRENLSSPNFISDPQSPMMVSELYSSVINAIDSRMQDT	782
Sbjct	721	LDLSLSPSPSPDFMSAVNEFVIRENLSSPNFISDPQSPMMVSELYSSVINAIDSRMQDT LDLSLSPSPSPDFMSAVNEFVIRENLSSPNFISDPQSPMMVSELYSSVINAIDSRMQDT	780
Query	783	NVCGKEDFGDHTSLNVQLRCRVVAQDSHFSIQTIKEDLCHFRFTVQKEQCDFNSLKCT NVCGKEDFGDHTSLNVQLRCRVVAQDSHFSIQTIKEDLCHFRFTVQKEQCDFNSLKCT	842
Sbjct	781	NVCGKEDFGDHTSLNVQLRCRVVAQDSHFSIQTIKEDLCHFRFTVQKEQCDFNSLKCT NVCGKEDFGDHTSLNVQLRCRVVAQDSHFSIQTIKEDLCHFRFTVQKEQCDFNSLKCT	840
Query	843	AVEIRNIIEKVKSLEITLKEKHQKELLSLKNEYEGKLDGLIKETEENENKIKKLKGLV AVEIRNIIEKVKSLEITLKEKHQKELLSLKNEYEGKLDGLIKETEENENKIKKLKGLV	902
Sbjct	841	AVEIRNIIEKVKSLEITLKEKHQKELLSLKNEYEGKLDGLIKETEENENKIKKLKGLV AVEIRNIIEKVKSLEITLKEKHQKELLSLKNEYEGKLDGLIKETEENENKIKKLKGLV	900
Query	903	CLEEVQNKDNEFALVXKHEKAIVICIQNEKDQKILEMENIMHSNCEIKELQSGREIVLE CLEEVQNKDNEFALVXKHEKAIVICIQNEKDQKILEMENIMHSNCEIKELQSGREIVLE	962
Sbjct	901	CLEEVQNKDNEFALVXKHEKAIVICIQNEKDQKILEMENIMHSNCEIKELQSGREIVLE CLEEVQNKDNEFALVXKHEKAIVICIQNEKDQKILEMENIMHSNCEIKELQSGREIVLE	960
Query	963	DLKKLHVENDEKQLLRLAELQSLQSHLKELEDTLQVARIQEFKVMTHDRVSLLEELKE DLKKLHVENDEKQLLRLAELQSLQSHLKELEDTLQVARIQEFKVMTHDRVSLLEELKE	1022
Sbjct	961	DLKKLHVENDEKQLLRLAELQSLQSHLKELEDTLQVARIQEFKVMTHDRVSLLEELKE DLKKLHVENDEKQLLRLAELQSLQSHLKELEDTLQVARIQEFKVMTHDRVSLLEELKE	1020
Query	1023	NQQTINQIQESHABI IQEKEKQIQELKIKVSDLSOTRCKLEVELALKEATDEIKILLEE NQQTINQIQESHABI IQEKEKQIQELKIKVSDLSOTRCKLEVELALKEATDEIKILLEE	1082
Sbjct	1021	NQQTINQIQESHABI IQEKEKQIQELKIKVSDLSOTRCKLEVELALKEATDEIKILLEE NQQTINQIQESHABI IQEKEKQIQELKIKVSDLSOTRCKLEVELALKEATDEIKILLEE	1080
Query	1083	SRAQQKETLKSLEQSTENIRTEISKLNQIQDNNENYQVGLAELATIMITEKQICISEL SRAQQKETLKSLEQSTENIRTEISKLNQIQDNNENYQVGLAELATIMITEKQICISEL	1142
Sbjct	1081	SRAQQKETLKSLEQSTENIRTEISKLNQIQDNNENYQVGLAELATIMITEKQICISEL SRAQQKETLKSLEQSTENIRTEISKLNQIQDNNENYQVGLAELATIMITEKQICISEL	1140
Query	1143	TSRHEEESNITLKAELNKVTSILHNQAFIEIKNLKEQIIELOKSLDSELSALERQKDEKITQ TSRHEEESNITLKAELNKVTSILHNQAFIEIKNLKEQIIELOKSLDSELSALERQKDEKITQ	1202
Sbjct	1141	TSRHEEESNITLKAELNKVTSILHNQAFIEIKNLKEQIIELOKSLDSELSALERQKDEKITQ TSRHEEESNITLKAELNKVTSILHNQAFIEIKNLKEQIIELOKSLDSELSALERQKDEKITQ	1200
Query	1203	QEEKYEAITQNLKEDRQKLVSSQEQDREQLIQKLNCEKDEAIQTALKEFKLEREVVEKEL QEEKYEAITQNLKEDRQKLVSSQEQDREQLIQKLNCEKDEAIQTALKEFKLEREVVEKEL	1262
Sbjct	1201	QEEKYEAITQNLKEDRQKLVSSQEQDREQLIQKLNCEKDEAIQTALKEFKLEREVVEKEL QEEKYEAITQNLKEDRQKLVSSQEQDREQLIQKLNCEKDEAIQTALKEFKLEREVVEKEL	1260
Query	1263	LEKVKHLENQIAKSPAIIDSTRGDSSELVABLQELQEEKAKFLEQLQEEQEKRRNVEQMNV LEKVKHLENQIAKSPAIIDSTRGDSSELVABLQELQEEKAKFLEQLQEEQEKRRNVEQMNV	1322
Sbjct	1261	LEKVKHLENQIAKSPAIIDSTRGDSSELVABLQELQEEKAKFLEQLQEEQEKRRNVEQMNV LEKVKHLENQIAKSPAIIDSTRGDSSELVABLQELQEEKAKFLEQLQEEQEKRRNVEQMNV	1320
Query	1323	RTSLIAEQQNFNTVLTREKMRKENIINDSLKSTMQQERDKDILTESLSEDRARILLE RTSLIAEQQNFNTVLTREKMRKENIINDSLKSTMQQERDKDILTESLSEDRARILLE	1382
Sbjct	1321	RTSLIAEQQNFNTVLTREKMRKENIINDSLKSTMQQERDKDILTESLSEDRARILLE RTSLIAEQQNFNTVLTREKMRKENIINDSLKSTMQQERDKDILTESLSEDRARILLE	1380
Query	1383	EKKKLEEEVSKLRSSSFVPSPVYATAPELYGACAPELPGESDRSAVETADEGRVDSAMET EKKKLEEEVSKLRSSSFVPSPVYATAPELYGACAPELPGESDRSAVETADEGRVDSAMET	1442
Sbjct	1381	EKKKLEEEVSKLRSSSFVPSPVYATAPELYGACAPELPGESDRSAVETADEGRVDSAMET EKKKLEEEVSKLRSSSFVPSPVYATAPELYGACAPELPGESDRSAVETADEGRVDSAMET	1440
Query	1443	SMSSVQENIHLSEEKQRMILERTILQKEEENKRLNQRLMSQMSVSSSRHSEKIAIRD SMSSVQENIHLSEEKQRMILERTILQKEEENKRLNQRLMSQMSVSSSRHSEKIAIRD	1502
Sbjct	1441	SMSSVQENIHLSEEKQRMILERTILQKEEENKRLNQRLMSQMSVSSSRHSEKIAIRD SMSSVQENIHLSEEKQRMILERTILQKEEENKRLNQRLMSQMSVSSSRHSEKIAIRD	1500
Query	1503	PQVGDVLVLIILDERHDNYVLTFTVSPPLYFLHSESLPALDLKPSAGASRRFWVLGKVMKEK PQVGDVLVLIILDERHDNYVLTFTVSPPLYFLHSESLPALDLKPSAGASRRFWVLGKVMKEK	1562
Sbjct	1501	PQVGDVLVLIILDERHDNYVLTFTVSPPLYFLHSESLPALDLKPSAGASRRFWVLGKVMKEK PQVGDVLVLIILDERHDNYVLTFTVSPPLYFLHSESLPALDLKPSAGASRRFWVLGKVMKEK	1560

Art Unit: 1642

Query	1563	YCQAKKAQNRPKVPLGTRKPYRVKAVSWNKKV	1593
		YCQAKKAQNRPKVPLGTRKPYRVKAVSWNKKV	
Sbjct	1561	YCQAKKAQNRPKVPLGTRKPYRVKAVSWNKKV	1591

CPU time:	0.04 user secs.	0.03 sys. secs	0.07 total secs.
-----------	-----------------	----------------	------------------